Previous 10 | Next 10 |
UroGen (NASDAQ: URGN ) is a clinical stage biopharmaceutical company involved in the development of new treatment options with a focus on uro-oncology. In this article, I will try to explain my skepticism on the company's new drug candidates. The company’s new approach is based on t...
UGN-101 and UGN-102 Demonstrate Positive Clinical Data in Low-Grade Upper Tract Urothelial Cancer (LG UTUC) and Low-Grade Non-Muscle Invasive Bladder Cancer (LG NMIBC) UGN-101 Final Data Modules for NDA Submission On-Track for Q4 2019 UGN-101 Plans for Launch Readiness by January ...
Thinly traded UroGen ( URGN -5.5% ) slips on almost triple normal volume, albeit on turnover of only 608K shares, on the heels of updated data on candidates UGN-101 and UGN-102 presented during its Investor Day today. More news on: UroGen Pharma Ltd., Healthcare stocks news, Stocks on ...
UGN-101: Consistent Complete Response (CR) Rate of 59 Percent in Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Durability of Response Determined to be 89 Percent at Six Months and 84 Percent at 12 Months Rolling NDA Submission on Track for Q4 2019 with Plann...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Company to Also Participate in September Investor Conferences UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it will host an Investor Day on September 24, 2019 in New York w...
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced the grants of inducement restricted stock units (“RSUs”) to 15 new employees in connection with their employment with UroGen...
UroGen Pharma Ltd. (URGN) Q2 2019 Earnings Conference Call August 12, 2019, 08:30 AM ET Company Participants Catherine Bechtold - Director of Corporate Communications & IR Elizabeth Barrett - President, CEO Mark Schoenberg - Chief Medical Officer Peter Pfreundschuh - CFO &a...
UroGen Pharma (NASDAQ: URGN ): Q2 GAAP EPS of -$1.08 beats by $0.13 . More news on: UroGen Pharma Ltd., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-15 04:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 07:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ord...